Biocartis Group Market capitalization 2024

Biocartis Group Market capitalization

17.56 M EUR

Biocartis Group Dividend yield

Ticker

BCART.BR

ISIN

BE0974281132

WKN

A14R82

In 2024, Biocartis Group's market cap stood at 17.56 M EUR, a -48.4% increase from the 34.03 M EUR market cap in the previous year.

The Biocartis Group Market capitalization history

YEARREVENUE (undefined EUR)GROSS MARGIN (%)NET INCOME (undefined EUR)
2025e10326,88-
2024e78.2835,36-
2023e59.7446,34-
202257.4848,16-
202148.2729,72-
202043.1339,06-
201937.4443,04-
201827.8144,81-
201720.9658,62-
201612.156,03-
201513.3380,19-
20148.4850,65-
20138.3377,07-
20123.5568,17-

Biocartis Group Aktienanalyse

What does Biocartis Group do?

Biocartis Group NV is a Belgian biotechnology company specializing in the development and marketing of innovative diagnostic test systems. The company was founded in 2007 and is headquartered in Mechelen, Belgium. Biocartis focuses on various disease areas such as gynecology, oncology, infectious diseases, and immunology. Biocartis' business model is based on a unique diagnostic test system called Idylla, which allows for rapid testing within hours instead of the usual weeks. The Idylla platform also offers high accuracy in identifying biomarkers and easy handling for medical personnel. The company has certified distribution partners worldwide to support the marketing and sales of Biocartis products. Biocartis collaborates closely with pharmaceutical companies, medical laboratories, and clinics globally to deliver the best results for its customers. The company also has partnerships with other biotech companies like Merck and Genomic Health to support the development of its diagnostic tests. Biocartis offers a wide range of diagnostic tests for various cancer types, gynecology, and infectious diseases. Their tests help physicians identify the type and extent of tumors and monitor patients' health status. Through the development and marketing of innovative diagnostic test systems, Biocartis aims to improve disease diagnosis and monitoring, ultimately enhancing treatment for patients worldwide. Overall, Biocartis is a leading company in the biotechnology industry specializing in the development and marketing of innovative diagnostic test systems for various disease areas. With its certified distribution partners and partnerships with other biotech companies, Biocartis has a strong presence in the global market and is well positioned to continue being a key player in the biomedical diagnostics industry. Biocartis Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Biocartis Group's Market Capitalization

Biocartis Group's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Biocartis Group's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Biocartis Group's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Biocartis Group’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Biocartis Group Stock

What is the current Biocartis Group market capitalization?

The current market capitalization of Biocartis Group is 17.56 M EUR.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Biocartis Group.

How has the market capitalization of Biocartis Group developed in recent years?

The market capitalization of Biocartis Group has increased/decreased by -48.4% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Biocartis Group?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Biocartis Group?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Biocartis Group have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Biocartis Group pay?

Over the past 12 months, Biocartis Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biocartis Group is expected to pay a dividend of 0 EUR.

What is the dividend yield of Biocartis Group?

The current dividend yield of Biocartis Group is .

When does Biocartis Group pay dividends?

Biocartis Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biocartis Group?

Biocartis Group paid dividends every year for the past 0 years.

What is the dividend of Biocartis Group?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biocartis Group located?

Biocartis Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biocartis Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biocartis Group from 5/15/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/15/2024.

When did Biocartis Group pay the last dividend?

The last dividend was paid out on 5/15/2024.

What was the dividend of Biocartis Group in the year 2023?

In the year 2023, Biocartis Group distributed 0 EUR as dividends.

In which currency does Biocartis Group pay out the dividend?

The dividends of Biocartis Group are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Biocartis Group

Our stock analysis for Biocartis Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocartis Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.